330
Table 7.3 The historical landmarks of amphiphilic cyclodextrin-based nanoparticles containing
anticancer and antimicrobial drugs including gene delivery to facilitate improved drug loading
capacity, significant cytotoxicity, and vectorized gene delivery
Drug/
mechanism
Amphiphilic
cylodextrin
Indication
Outcomes
offered by
amphiphilic
cylodextrin
nanoparticles
Historical
landmarks
References
Bifonazole
and
clotrimazole
6-N-capro-βcyclodextrin
Antifungal
Improved drug
loading
capacity
First report on
antifungal drug
with amphiphilic
cyclodextrin
Memişoğlu
et al.
(2003)
Tamoxifen
citrate
β-Cyclodextrin Anticancer Improved
loading
capacity and
cytotoxicity
Bilensoy
et al.
(2005)
Amphiphilic
β-cyclodextrin
nanosphere
β-Cyclodextrin In vivo
tissue
distribution
No particular
sign of toxicity
First report of
in vivo behavior
of amphiphilic
cyclodextrin
nanoparticles
Gèze et al.
(2007)
Paclitaxel
Cyclodextrin
derivatives
Anticancer No effect on
cell
proliferation
and no
hemolysis of
red blood cells
Bilensoy
et al.
(2008a, b)
Camptothecin β-Cyclodextrin Anticancer Improved
release profiles
and significant
antitumor
efficacy
First comparison
of amphiphilic
cyclodextrin
nanoparticles
with polymeric
analogues
Çirpanli
et al.
(2009)
Camptothecin Cyclodextrin
Anticancer Significant
anticancer
efficacy
Çirpanli
et al.
(2011)
Docetaxel
Cyclodextrin
heptakis
Anticancer Prolonged cell
arrest in mitosis
Quaglia
et al.
(2009)
Acyclovir
Fluorinated
alphacyclodextrin
hexakis
Antiviral
Improved
encapsulation
efficiency,
sustained
release of
acyclovir
First report on
antiviral drug
nanoparticles
based on
amphiphilic
cyclodextrin
Ghera et al.
(2009)
Plasmid DNA Polycationic
cyclodextrin
Transfection
capability
Vectorized
gene delivery
DíazMoscoso
et al.
(2011)
(continued)
A. Pandey